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Ubiquitin-specific protease 15 (USP15) regulates important
cellular processes, including transforming growth factor 
(TGF-) signaling, mitophagy, mRNA processing, and innate
immune responses; however, structural informationonUSP15’s
catalytic domain is currently unavailable. Here, we determined
crystal structures of the USP15 catalytic core domain, revealing
a canonical USP fold, including a finger, palm, and thumb
region. Unlike for the structure of paralog USP4, the catalytic
triad is in an inactive configuration with the catalytic cysteine
10 Å apart from the catalytic histidine. This conformation is
atypical, and a similar misaligned catalytic triad has so far been
observed only for USP7, although USP15 and USP7 are differ-
ently regulated. Moreover, we found that the active-site loops
are flexible, resulting in a largely open ubiquitin tail–binding
channel. Comparison of the USP15 and USP4 structures points
to a possible activation mechanism. Sequence differences
between these two USPs mainly map to the S1 region likely to
confer specificity, whereas the S1 ubiquitin–binding pocket is
highly conserved. Isothermal titration calorimetry monoubiq-
uitin- and linear diubiquitin-binding experiments showed
significant differences in their thermodynamic profiles, with
USP15displaying a lower affinity formonoubiquitin thanUSP4.
Moreover, we report that USP15 is weakly inhibited by the anti-
neoplastic agentmitoxantrone in vitro. AUSP15–mitoxantrone
complex structure disclosed that the anthracenedione interacts
with the S1 binding site. Our results reveal first insights into
USP15’s catalytic domain structure, conformational changes,
differences between paralogs, and small-molecule interac-
tions and establish a framework for cellular probe and inhib-
itor development.
Ubiquitin-specific proteases (USPs)5 are key players in the
regulation of important cellular signaling pathways through
catalyzing the deconjugation reaction of ubiquitin from sub-
strate proteins (1). Although the dysregulation or malfunction
of USPs has been linked to diseases as varied as cancer, neuro-
degenerative disorders, and a host’s response to infection (2, 3),
for most of these enzymes, there is a lack of molecular under-
standing regarding conformational changes, regulation of
catalysis, and specificity. Structural information is key to shed-
ding light on their mechanism and substrate interactions and
can aid small-molecule inhibitor development. The multifunc-
tional protease USP15 regulates several important pathways
in health and disease (4), including TGF- (5), IGF-I (6), innate
immune signaling (7), mRNA processing (8), and mitophagy
(9). Furthermore, USP15 can promote new protein synthesis
(10), depletion results inDNAdouble strand repair defects (11),
andUSP15was shown to regulate the ligaseMDM2with effects
on the stability of p53 in cancer cells and the T-cell transcrip-
tion factor, NFATc2 (12). USP15 is also dysregulated in many
cancers (12–14), and knockdown of USP15 rescues the
mitophagy defect of Parkinson’s disease patients’ fibroblasts
(9). USP15 has two paralogs, themore closely related USP4 and
more distant USP11, which we refer to as the DUSP–UBL fam-
ily of USPs (15–18). Viability in mice is contingent on a func-
tional copy of USP4 or USP15 (18), and the two paralogs share
a degree of functional overlap in mRNA splicing (8, 19, 20),
TGF- signaling (21), and RIG-I–mediated antiviral signaling
(7, 22), albeit mostly not acting on the same substrates in these
pathways.
USP11 typically engages in different protein interactions
(23). USP15, USP4, and USP11 share the same overall domain
structure, including an N-terminal domain present in USPs
(DUSP) and ubiquitin-like (UBL) domain followed by a prote-
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ase domain that harbors a300-amino acid insertion predicted
to contain a second UBL domain (Fig. 1A). These ancillary
domains affect the catalytic function in different ways, whereby
they regulate the catalytic activity of USP4 (24), whereas
USP11’s activity is not significantly modulated by their pres-
ence using a model substrate (17, 24). The role of ancillary
domains in USP15 is less clear, with only a minor regulatory
role on catalysis attributed to the USP15 DUSP–UBL domains
so far (24). We and others previously determined crystal
structures of the USP15 N-terminal domains (15, 16), but no
structural information on the catalytic domain is available at
present.
Here, we describe the structure of the USP15 catalytic core
and compare it with the structure of paralog USP4 (24). Based
on this analysis, we highlight key differences that may be
responsible for altered specificity and regulation and propose a
hypothetical model for conformational changes between “open
inactive” and “closed catalytically competent” conformations.
Furthermore, we determined the structure of a USP15–
mitoxantrone complex, a Food and Drug Administration–
approved antineoplastic drug (25), which has multiple cellular
targets (26), including USP11 (25), that shows a novel binding
mode for a USP ligand. Together, these findings allow novel
insights into the USP15 structure, substrate recognition, and
differences between close USP paralogs, and additionally they
provide tools for structure-based drug design.
Results
The USP15 catalytic core structure displays amisaligned
catalytic triad
To determine the structure of the USP15 catalytic domain,
we designed a construct spanning the catalytic core region
(USP15-D1D2; Fig. 1A), with the insert harboring a predicted
UBL domain replaced by a short linker (based on the USP8
structure, PDBentry 2GFO (27)). Enzymekinetic analysis of the
catalytic core compared with full-length USP15 (FL-USP15)
using the fluorogenic model substrate ubiquitin-7-amido-4-
methylcoumarin (AMC) revealed that the kinetic parameters
between the two are comparable, with similar Km and kcat val-
ues (Fig. 1B). This showed that USP15-D1D2 fully retained its
activity and suggests that the ancillary domains do not play a
significant regulatory role in catalysis. USP15-D1D2 was then
subjected to sparse matrix crystallization screening, and crys-
tals were obtained in conditions using 0.1 M Tris-Cl, pH 8.5,
20% PEG 2000 (see “Experimental procedures”). After optimi-
zation, crystals of space group P21 diffracted to 2 Å resolution
and contained onemolecule in the asymmetric unit. The struc-
ture was solved by molecular replacement using coordinates of
paralog USP4 (PDB entry 2Y6E (24)) as a search model (data
collection and refinement statistics are shown in Table 1). The
USP15 catalytic core displays the characteristic USP protease
domain fold, including a finger, palm, and thumb region (Fig.
1C). A C-terminal tail structure unique to USP15 is rich in
Figure 1. Kinetic parameters and crystal structure of the USP15 catalytic core. A, schematic representation of the human USP15 domain structure high-
lighting the location of the catalytic core region encompassing the subdomain halves D1 andD2 in blue and the catalytic triad residues (green) with additional
domains labeled asDUSP (domain present in USPs) andUBL (ubiquitin-like). B, kinetic assays of FL-USP15 and USP15-D1D2 using ubiquitin-AMC as a substrate
with FL-USP15 in green and USP15-D1D2 in blue. Each point represents the mean for data points measured in triplicate. Values for Vmax and Km were used to
calculate the turnover number, kcat, and catalytic efficiency, kcat/Km, and are listed in the table on the right. Error bars, S.E. C, cartoon representation of the crystal
structure of the USP15 catalytic core with catalytic triad residues shown as a green stick representation and active-site loops and key secondary structure
elements labeled.D,B-factor “putty representation” of USP15-D1D2highlighting the variationofB-factorswhere the thickness is proportional to its localB-factor
and thus its flexibility and is color-coded blue to red (for lowest to highest B-factors). The approximate location of the distal ubiquitin is modeled as a
semitransparent surface representation (red) into the S1 binding site and shows that the finger region will need to flex to accommodate ubiquitin.
USP15 catalytic domain structure
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aromatic residues and folds back onto the catalytic core in the
structure and is located on the opposite face to the distal ubiq-
uitin S1 binding pocket. The active-site loop regions between
helices 5 and 6, also referred to as the switching loop (SL;
including residues Pro342–Gln353; PQFSGYQQQDCQ), and
residues between 12 and 13, referred to as blocking loop 1
(BL1; residues Ser810–Arg816; SYSRYMR) that engage in USP
distal ubiquitin binding are partially flexible (unrestricted by
crystal contacts and not visible in the electron density; indi-
cated as dotted lines in Fig. 1C). As a consequence, the free
enzyme structure of USP15 has a largely open catalytic channel
conformation for accommodating the distal ubiquitin tail that
harbors the two C-terminal glycines. Modeling of ubiquitin
into the central binding cavity by superposition of the USP2–
ubiquitin complex structure (PDB entry 2HD5 (28)) reveals
that additional conformational changes in the finger region,
including the zinc finger ribbon linking the two subdomainsD1
and D2, are required to accommodate the distal ubiquitin core
and avoid steric clashes (Fig. 1D). Mapping B-factors indicative
of mobile regions onto the structure reveals that residues likely
to undergo conformational changes upon substrate binding
also display higher B-factors (Fig. 1D).
Interestingly, the USP15 structure shows the catalytic triad
in an inactive conformation with the catalytic cysteine (Cys269)
in the catalytic cleft loop between 1 and 1 (CCL; residues
Ser263–Phe270; SNLGNTCF) located10 Å away from the cat-
alytic histidine (His862) (Fig. 1C). The CC loop also displays
higher B-factors compared with surrounding residues, indicat-
ing that this region can readily adopt different conformations.
Equally, residues in the blocking loop 2 between 15 and 16
(BL2; Gly856–Gly860; residues GGMGG) are partially flexible
and associated with higher B-factors, suggestive of higher
mobility. In contrast to Cys269, the side chains of catalytic triad
residues His862 (on 16 at the C-terminal end of BL2) and
Asp879 (end of 17) are “pre-aligned” for catalysis and within
hydrogen-bonding distance (Fig. 1C).
Differences between USP4 and USP15
USP15 shares 56.9% sequence identity with paralog USP4
over the entire length of its sequence, 57.8% sequence identity
in the catalytic domain, and 77.4% in the catalytic core region
D1D2.We therefore compared our structure with the available
structure of the USP4 catalytic core (USP4-D1D2; PDB entry
2Y6E (24)) by superimposing the two structures (root mean
square deviation of 0.916 Å over 315 equivalent C positions).
In contrast toUSP15, the catalytic triad in theUSP4 structure is
pre-aligned in a catalytically competent configuration. Both
structures were determined in the absence of ubiquitin; USP4
was captured with a -mercaptoethanol (BME) molecule cova-
lently linked to the catalytic cysteine (Fig. 2, A and B). These
differences in the catalytic competency states of the catalytic
triad coincide with different conformations of USP15 Phe270
compared with USP4 Phe312, the neighboring residue to the
catalytic cysteine in the CC loop (Fig. 2, B andC). In our USP15
structure, the switching loop is partially flexible (Fig. 1C),
whereas in the USP4 structure it is ordered, possibly aided by
interactions with neighboring molecules in the crystal lattice
(24). In addition, the C-terminal end of the switching loop and
start of helix 6 are different in the two structures: in USP15
following residues of the SL, helix 6 starts with residue Leu355,
whereas in USP4, equivalent residues before this leucine adopt
an additional helical turn starting with Ser394 (Fig. 2B). In
USP15, Gln349 in the SL is flexible, but in USP4, the equivalent
Gln391 reaches across the channel possibly aided by interac-
tions with the BME molecule involving main chain NH and
carbonyl groups from Gln391 and Gln392 and Val879 in the BL2.
As a result, the ubiquitin C-terminal GG tail–binding channel
is mostly open in USP15, whereas it is closed in the USP4 struc-
ture (Fig. 2, C and D).
At the N-terminal end of the SL, the side chain of Phe340
(USP15) adopts a conformation (“in”), which is different from
Phe382 inUSP4 (“out”), whereasUSP15Pro342 andGln343 adopt
conformations similar to those of their USP4 counterparts. In
turn, USP15 Met305, which packs against the side chain of
Phe340, also adopts different conformations compared with
USP4 (Met347 and Phe382) (Fig. 2C). These differences also
coincide with different side chain conformations of USP15
Phe358 (out) and USP4 Phe400 (in) in helix 6, respectively (Fig.
2C). The preceding 5 helix is located further “in” in USP15,
whereas in USP4, the ordered SL contains a helical turn (USP4
residues 384–387 PQFS), whereby the USP4 Phe386 side chain
packs against residues Leu397, Phe312, and Phe400 in the core.
The corresponding residues of the same amino acid
sequence in the USP15 structure (Pro342–Ser345) are partly
defined in the electron density due to flexibility. A USP15–
USP4 amino acid sequence alignment in the SL region
reveals the only difference to be a cysteine residue (USP15
Cys352), which replaces a serine (Ser394) in USP4 (Fig. 2D and
Fig. S1). USP15 SL residue Cys352 is conserved across an
alignment of USP15 amino acid sequences, but in the crystal
Table 1
Crystallographic data collection and refinement statistics
USP15-D1D2
(USP15-free)
USP15-D1D2–
mitoxantrone
Data collection
Space group P21 P21
Cell dimensions
a, b, c (Å) 48.51, 62.62, 62.04 62.07, 94.39, 63.29,
 (degrees) 104.97 90.08
Resolution (Å) 1.98 2.09
Rmerge 0.111 (1.060)a 0.102 (1.619)
Rpim 0.074 (0.711) 0.052 (0.87)
I/I 4.7 (1.7) 9.9 (1.57)
CC1/2 0.991 (0.527) 0.998 (0.668)
Completeness (%) 97.7 (86.3) 98.8 (98.5)
Redundancy 3.0 (3.0) 4.8 (4.9)
Wilson B-factor (Å2) 33.0 38.1
Refinement
Resolution range (Å) 46.54–1.98 62.07–2.09
No. of reflections 24825 42810
Rwork/Rfree 0.198/0.234 0.203/0.251
No. of atoms 2734 5319
Protein 2602 5129
Other 1 37
Water 131 153
B-factors (Å2)
Protein 48.1 59.0
Ligand 88.3
Water 50.5 50.5
Root mean square deviations
Bond lengths (Å) 0.007 0.007
Bond angles (degrees) 0.794 0.904
a Values in parentheses are for the highest-resolution shell.
USP15 catalytic domain structure
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structure, it is not well-defined and therefore was not mod-
eled and assumed to be flexible.
We then mapped all residues that differ between USP15 and
USP4 across the catalytic core onto the USP15 surface and vice
versa, which revealed that residues in the distal ubiquitin-bind-
ing pocket are highly conserved betweenUSP15 andUSP4 (Fig.
2D). Greater variability in amino acids is observed in the S1
binding region, which engages a proximal ubiquitin moiety in a
polyubiquitin substrate or a different target substrate conju-
gated to the C-terminal tail of ubiquitin (Fig. 2D). Of note is
BL2, which in USP15 (GGMGG) is highly mobile due to the
presence of four glycines, whereas BL2 in USP4 contains fewer
glycine residues (GAMGV) and adopts a different conforma-
tion (Fig. 2A and Fig. S1), although both display high B-factors,
highlighting their mobility. Substitution of glycine for Val879 in
USP4may contribute to different BL2 conformations, as Val879
is positioned at the rim of the ubiquitin GG tail–binding chan-
nel (Fig. 2B). Other differences in the S1 area cluster in the loop
region between 4 and 5 (USP15 324–329 (KFSYVT) versus
USP4 366–371 (RDAHVA)), which is close to the linker region
that connects the catalytic core to theN-terminal UBL domain.
There, USP15 Phe325, Ser326, and Tyr327 are replaced by USP4
Asp367, Ala368, and His369, respectively. Other changes in this
area include USP15 Ser263 (USP4 Gly305), USP15 Ser882 (USP4
Asn901) and USP15 Thr885 (USP4 Leu904) (Fig. 2D). In addition
to the S1 region, other significant structural differences occur
Figure 2. Comparison of USP4 andUSP15 catalytic core crystal structures. A, superposition of cartoon representations of the USP15 structure (in bluewith
catalytic triad residues in green) and the USP4 structure with-mercaptoethanol bound to the catalytic cysteine (in graywith catalytic triad residues shown as
sticks inwheat; PDB ID 2Y6E (24)). Note the differences in the catalytic triad residues and surrounding loop regions CCL, SL, BL1, and BL2. B, close-up view of the
active-site region showing the different conformations of USP15 (blue) and USP4 (gray) residues in the CCL, SL, and BL2. The approximate location of the
ubiquitin C-terminal tail is depicted in a red semitransparent cartoon representation. C, conformational differences of selected labeled residues shown in stick
representation inUSP15 (inblueon the left) andUSP4 (ingrayon the right). Equivalent residues inboth structures located in the switching loopSLarehighlighted
in orange (note that in USP15, the SL is largely flexible, indicated by a dotted line), whereas other intervening residues are highlighted inmagenta. The catalytic
cysteines are depicted in wheat, and the histidine and aspartate of the catalytic triad are colored in green. D, surface representations of USP15 (left) and USP4
(right) catalytic cores. Residues that are dissimilar between the two paralogs are highlighted in yellow, residues with weakly similar properties are colored in
orange, and residues with similar properties are colored in blue. The light blue or gray background, respectively, denotes fully conserved residues between
USP15 and USP4. Catalytic triad residues are highlighted in green, and selected residues are labeled. Note the differences in conservation between the large
distal ubiquitin-binding cavity (S1 pocket) and the S1 regions in both structures.
USP15 catalytic domain structure
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on the surface of helix 7 at the opposite site of the distal ubiq-
uitin-binding pocket with a charge reversal (USP15 Glu391 ver-
susUSP4 Lys433) and differences in the location of hydrophobic
and hydrophilic residues (USP15 Leu398-Lys399 versus USP4
Arg440-Leu441).
To evaluate the substrate- and product-binding behavior of
the USP15 and USP4 catalytic cores, we measured dissociation
constants of inactive mutants USP15-D1D2 C269S and USP4-
D1D2C311S withmonoubiquitin and linear diubiquitin (occu-
pying either the S1 or both S1 and S1 pockets, respectively).
Remarkably, the results showed that monoubiquitin binds sig-
nificantly tighter to USP4, whereas for linear diubiquitin, the
dissociation constant for the interaction with USP15 was of the
same order of magnitude compared with USP4 (Fig. 3). Inter-
estingly, the enthalpy and entropy contributions associated
with the binding events differed significantly, with USP15 dis-
playing endothermic binding behavior, whereas USP4 dis-
played exothermic binding behavior for mono- and linear diu-
biquitin at 25 °C. We then further investigated the molecular
basis of these differences through mutational analysis by swap-
ping residues in the USP15 BL2 for the respective USP4 resi-
dues. These ITC experiments were carried out at 37 °C to
record good signal/noise ratios for the USP15-D1D2 G860V
and USP15-D1D2 bl2usp4 (G857A/G860V) mutants, which
produced small heat change upon ubiquitin binding at 25 °C
(data not shown). The USP15-D1D2 interaction with ubiquitin
was exothermic under these conditions. These experiments
showed that thermodynamic parameters H and S for the
interaction of monoubiquitin with the USP15-D1D2 G860V
and USP15-D1D2 bl2usp4 (G857A/G860V) mutants gradually
changed with the stepwise substitution of the glycines in the
BL2 approaching those obtained for USP4-D1D2 (Fig. 4). The
difference in the dissociation constants for the interactions
between active USP15-D1D2 and USP4-D1D2 and monoubiq-
uitin was less pronounced in these experiments compared with
the interaction with the catalytic Cys-to-Ser mutants. The SL
has only one difference in the amino acid sequence between
USP15 and USP4, and the SL mutant (USP15-D1D2 C352S)
Figure 3.Monoubiquitin and linear diubiquitin binding toUSP4 andUSP15 active-sitemutants. ITC analyses of raw datameasured at 25 °C and binding
isotherms fitted to a one-site bindingmodel of USP15-D1D2C269S andUSP4-D1D2C311Swithmonoubiquitin and linear diubiquitin, respectively. Respective
dissociation constants are listed in the table below, and associated G, TS, and H values are graphically depicted on the right to highlight different
contributions to the binding.
USP15 catalytic domain structure
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displayed similar binding parameters compared with USP15-
D1D2 (Fig. S2).
Comparisonwith other USPs
The majority of USP catalytic domain structures available to
date were determined in complex with either ubiquitin or a
covalent inhibitor including USP2 (28), USP4 (24), USP5 (29),
USP7 (30), USP12 (31), USP18 (32), USP14 (33), USP21 (34),
USP30 (35), USP46 (36), and CYLD (37). Structures that do not
have a ligand or ubiquitin covalently bound to the catalytic cys-
teine are available forUSP7 (PDBcodes 1NB8, 2F1Z, 4M5X (30,
38, 39)), USP14 (PDBcode 2AYN (33)), CYLD (PDBcode 2VHF
(40)), USP8 (PDB code 2GFO (27)), USP18 (PDB code 5CHT
(32)), and USP12 (PDB codes 5K1B and 5K16 (41)). Among the
latter structures, the USP15 catalytic core is most closely
related to USP8 (46% sequence identity) followed by USP12
(26.32% sequence identity), whereas it is more distantly related
to USP7 (21.99% sequence identity), USP14 (19.94% sequence
identity), and CYLD (11.8% sequence identity).
Apart from USP7, the catalytic triad residues in these struc-
tures are largely pre-aligned in close proximity, and the cata-
lytic cysteine is located in the first turn of helix 1 (Fig. 5,A and
B). In our USP15 structure, the distance between the catalytic
cysteine thiol group (Cys269) and the catalytic histidine imidaz-
ole (His862) is about 10 Å, which is even slightly farther away
than the catalytic cysteine in the USP7 free enzyme structures
(Fig. 5C) and is part of an extended CC loop. In USP7, the
conformational changes between free and ubiquitin-bound
forms involve different conformations of the aromatic residue
C-terminal to the catalytic cysteine in the CC loop (Phe270 in
USP15 and Phe312 in USP4) (30, 42). USP7 Tyr224 flips in and
out with concomitant conformational changes in the SL and
CC loop, which together determine whether the position of the
catalytic cysteine is pre-aligned in the catalytic triad. However,
in USP7, the SL region has a different sequence and structure
(Fig. 5A and Fig. S1) and is ordered in the free as well as ubiq-
uitin suicide inhibitor–bound forms possibly aided by crystal
contacts, whereas in the USP15 structure, the SL is flexible and
largely not visible in the electron density. In a CYLD structure
(PDB code 2VHF), the SL is also observed as flexible in the
crystal structure, but otherwise, the SL is ordered in other USP
structures. The only highly conserved residue in the SL region
among these USPs is the glutamine residue (part of the so-
calledUSPQQDbox (43)) that closes over the ubiquitinGG tail
channel in ubiquitin-bound USP structures, including USP2
(28), USP7 (30), USP21 (34), USP46 (36), USP12 (31), and
USP14 (33); in USP30, it is a glutamic acid, Glu159 (35).
Mitoxantrone inhibits the activity of USP15 and occupies the
S1 region of the catalytic core
We subsequently tested whether USP15 is inhibited by
mitoxantrone using a diubiquitin gel shift cleavage assay, as this
agent has previously been shown to inhibit the homolog USP11
(25). We determined that USP15 is weakly inhibited by mito-
Figure 4. Influence of blocking loop 2 mutations on the ubiquitin-binding behavior of USP15. ITC raw data and binding isotherms fitted to a
one-site binding model of USP15-D1D2, USP15-D1D2 G860V, USP15-D1D2 bl2usp4, and USP4-D1D2 with monoubiquitin at 37 °C. The respective
dissociation constants are given in the table below on the right, and the associated thermodynamic parameters G, H, and TS are graphically
represented on the left.
USP15 catalytic domain structure
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xantrone with an IC50 value of 33 11 M (Fig. 6A and Fig. S3).
Co-crystallization trials in the presence of excess mitoxantrone
yielded crystals of intense blue color that diffracted to 2.1 Å
resolution (data collection and refinement statistics are shown
in Table 1). After molecular replacement, an additional planar
shape of electron density was visible in the vicinity of the BL2
region near the catalytic histidine that corresponded to the
anthracenedione structure of mitoxantrone (Fig. 6B). The cat-
alytic triad in this different crystal form is also misaligned in
both USP15 copies present in the asymmetric unit in a similar
configuration to the USP15-free enzyme structure (Fig. 6C).
This USP15–mitoxantrone complex structure revealed pre-
dominantly hydrophobic interactions between mitoxantrone
and USP15 residues Tyr855, Gly856, Gly860, His862, which are
located in the BL2 region (Fig. 6D). In addition, one of mitox-
antrone’s side arms contacts the CC loop Asn264, although the
density is weaker comparedwith themitoxantrone anthracene-
dione core (Fig. 6B). There are no interactions of mitoxantrone
with other neighboring USP15 molecules in the crystal lattice.
This binding site coincides with the S1 region of USP15, sug-
gesting a rationale for the inhibition observed (Fig. 6E). In this
position, mitoxantrone is expected to compete with substrate
interactions, as indicated by modeling a diubiquitin molecule
into the binding site based on a superposition with a USP30
C77A Lys6-linked diubiquitin structure (35), the closest avail-
able USP structure in complex with a substrate (Fig. 6E). Super-
position of theUSP15-free andmitoxantrone-bound structures
revealed that the BL2 becomes ordered, but no other major
conformational changes are observed upon mitoxantrone
binding.
Discussion
There are 58USPs in the human genome, but only for a small
subset is structural information on their catalytic domains
available to date. Most structures have been determined in
complex with ubiquitin or ubiquitin-based inhibitors. Here, we
determined the structure of the USP15 catalytic core domain,
which reveals a structure with a misaligned catalytic triad, with
the catalytic Cys269 andHis862 separated by a large distance and
active-site loop conformations not previously observed for any
other USP. Our USP15 structure compared with USP4 (24)
revealed several differences in the active-site and substrate-
binding regions, but the comparison may also suggest an acti-
vation pathway upon ubiquitin binding as outlined below.
The USP15 structure reported here displays a catalytically
incompetent open conformation of the ubiquitin C-terminal
tail–binding channelwith active-site loops not engaged in crys-
tal contacts, whereas a “closed” form of USP4 was previously
captured with a pre-aligned catalytic triad (24). The structural
comparison, partial functional overlap, high sequence conser-
vation in the S1 pocket, and the assigned roles and conforma-
tions of certain residues around the active site in other USPs
suggest that the two structures largely represent open (inactive)
and closed (active) conformational states, as the bound BME
in USP4 co-localizes with the expected position of the ubiq-
uitin tail (Fig. S4), and crystal packing interactions may have
Figure5.ComparisonwithotherUSPcatalytic core structuresdetermined in theabsenceofubiquitin.A, crystal structuresofUSP15 (blue) andUSP4 (PDB
code 2Y6E (24)), USP8 (PDB code 2GFO (27), USP7 (PDB code 4M5X (38)), USP14 (PDB code 2AYN (33)), andUSP12 (PDB code 5K16 (41)) shown in a gray cartoon
representationwith catalytic triad residues highlighted in green and BL1, SL, and BL2 loop regions each depicted in red. B, superposition of the same structures
as seen in A, highlighting the most variable regions in the structures. C, superposition of the active-site region of USP15 (blue) and USP7 (light blue), the only
knownUSP catalytic core structureswhose catalytic triad ismisaligned in a similarway in the free enzyme.Note thedifference in switching loop conformations
and the significant distances (Å) between the catalytic cysteines and histidines.
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promoted order in the USP4 switching loop. Substrate bind-
ing is likely to result in active-site rearrangement and align-
ment of the catalytic residues, which at least in part may
coincide with conformational changes observed between the
two structures.
In this scenario, possible conformational changes in USP15
upon substrate binding leading to the alignment of the catalytic
triad can be summarized as follows: (i) flexible-to-order transi-
tion of BL1 and (ii) flexible-to-order transition in parts of the
C-terminal end of the switching loop, including Glu354 reposi-
tioning to form a salt bridge with ubiquitin Arg72. The flexible
USP15 Cys352 would be expected to adopt an -helical confor-
mation extending6, as inUSP4 the equivalent residue Ser394 is
located on an additional6 helical turn and faces inward, form-
ing a hydrogen bond with Ser871 (USP15 Ser852). In this confor-
mation, USP15 Cys352 would displace the Phe270 side chain in
the CC loop to adopt a similar conformation as USP4 Phe312.
This in turn would require displacement of the catalytic Cys269
to avoid steric clashes and would result in the alignment of the
catalytic triad. As is typical for USP structures, the USP15 SL
Gln349 is expected to reposition to close over the ubiquitin GG
tail–binding channel. (iii) At the N-terminal end of the SL, a
flexible-to-order transition of USP15 Phe344 (USP4 Phe386)
could result in repacking of other hydrophobic residues, pre-
dominantly USP15 Phe358, Phe340, and Met305, and pushing
helix 5 outward. The hydrophobic residues involved are
Figure 6. Inhibition of USP15bymitoxantrone. A, IC50 curve formitoxantrone as an inhibitor of USP15 using diubiquitin gel shift cleavage assays. Error bars,
S.E. B,mFobsDFcalc omit electron densitymap calculatedwith themitoxantronemolecule removed contoured at 2.0with the density shown in light orange
and corresponding final model in an orange stick representation. C, cartoon representation of the USP15–mitoxantrone complex crystal structure. The USP15
protease domain is depicted in bluewith catalytic triad residues in green andmitoxantrone shown in a space-fill representation in orange.D, close-up viewof the
molecular basis of the interaction. Key residues involved in the interaction are labeled and shown as yellow sticks. Otherwise, the color code is the same as in C.
E, same representationof theUSP15–mitoxantrone complex as inCwith adiubiquitin substrate shownas a semitransparent surfacemodeled into theactive site
based on the orientation seen in the crystal structure of the USP30–Lys6-diubiquitin complex (PDB code 5OHP (35)) to highlight clashes with mitoxantrone
binding in the S1 pocket. F, superposition of available crystal structures of USP7 (gray) in complex with small-molecule inhibitors in magenta stick represen-
tations (PDB codes 5N9R, 5N9T, 5NGE, 5NGF, 5UQV, 5UQX, and 5WHC (49–51)) and USP2 (gray; PDB code 5XU8 (52)), highlighting the interaction locations in
predominantly the S1 pocket and active-site channel. USP15 is depicted in a blue cartoon representationwith mitoxantrone in orange. Catalytic triad residues
are depicted in green stick representations.
USP15 catalytic domain structure
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highly conserved in USP15 and USP4 across species, and a
USP4 SL F386G mutant was shown to increase the catalytic
activity of the USP4 catalytic domain (USP4-CD) activity by
affecting ubiquitin on and off rates (24).
A hypotheticalmodel of this proposed activationmechanism
upon ubiquitin binding for USP15 is shown in Fig. 7. In addi-
tion, flexing of the finger versus palm regions will need to
occur upon substrate binding to avoid steric clashes. Further
investigations, such as the determination of a USP15 sub-
strate- or product-bound structure and molecular dynamics
simulations will be required to confirm this mechanism.
Interestingly, differences between free and ubiquitin-bound
forms of USP7 also rely on conformational changes in the
switching and CC loops involving aromatic side chains, but the
involved residues and adopted conformations of the loop
regions, especially the switching loop, are different compared
with the proposed changes between USP15-free and substrate-
bound forms (42). Examples of unproductive misaligned cata-
lytic triads are also found among other deubiquitinating
enzyme families, such as ubiquitin C-terminal hydrolases
(UCH family) that involve conformational changes of aromatic
residues and OTULIN (OTU family), but in these cases, these
are mainly restricted to realignment of the catalytic histidines
that act as a general base (44).
On the other hand, we noted clear differences between
USP15 and USP4 that could contribute to different modes of
regulation and substrate specificities in line with previous
reports (24). The product (monoubiquitin)- and model sub-
strate (diubiquitin)-binding behavior determined by ITC indi-
cated that product inhibition plays a larger role for USP4 than
USP15 consistent with previous data, whereas both paralogs
engage a linear diubiquitin substrate with similar equilibrium
affinities. The dissociation constant formonoubiquitin binding
to the USP4-D1D2 catalytic core is comparable with the one
reported previously for USP4-CD and FL-USP4 (24). For
USP15-D1D2, both binding events are associated with endo-
thermic binding enthalpies at 25 °C, indicating an entropically
driven process. In contrast, USP4mono- and linear diubiquitin
interactions are enthalpically driven. In the absence of USP4
andUSP15 ubiquitin-bound structures, themolecular bases for
these differences are difficult to rationalize at present, as mul-
tiple factors will contribute, such as the release of bound water
molecules, conformational changes associatedwith the binding
events, and differences in interacting residues.
However, we identified that the BL2 influences the binding
parameters. The USP15 BL2 is more flexible due to the pres-
ence of an additional two glycine residues comparedwithUSP4.
Within the USP4 BL2, Val879 packs against Glu391 and is close
to the expected position of the ubiquitin tail. When we substi-
tuted the corresponding Gly860 in USP15 with a valine, the
USP15-D1D2 G860V mutant ubiquitin-binding parameters
were altered, confirming that this residue is involved in ubiqui-
tin binding. A USP15-D1D2 G857A/G860V mutant (USP15-
D1D2 bl2usp4) displayed a further change in the H and S
parameters associated with ubiquitin binding toward those
obtained for USP4 with a more favorable enthalpic contribu-
tion, but less favorable entropic contribution, whichmay reflect
additional order in the BL2 through interactions with the ubiq-
uitin tail (Fig. 4). The BL2 glycines in USP15 may therefore
contribute to differences in the ubiquitin discharge behavior
between USP15 and USP4 (24). The difference in sequence in
the switching loop (USP15 Cys352 to USP4 Ser394) had little
impact on the ubiquitin-binding properties (Fig. S2). It is evi-
dent that additional residues at the interface, and/or noninter-
acting regions through long-range effects, contribute to USP4
and USP15’s ubiquitin-binding behavior.
In USP4, the switching loop is ordered, possibly aided by
crystal contacts, and interacts with the N-terminal DUSP
domain (24), whereas in USP15, the SL is largely flexible in the
free enzyme structure, and the DUSP domain is not known to
interact with the catalytic core domain, probably due to differ-
ences in the N-terminal regions (15, 16, 24). In contrast to
USP4, we show that kinetic parameters of USP15-D1D2 are
very similar to FL-USP15; hence, the catalytic core does not rely
Figure7.HypotheticalmodelofanactivationmechanismtoaligntheUSP15catalytic triaduponsubstratebinding.A, superpositionofUSP15 (blue) andUSP4
(gray; PDB code 2Y6E (24)) crystal structures with possible conformational changes upon substrate binding to align the remote Cys269 into an active conformation
indicatedbasedon the twostructures.Hypothetical conformational changesof selected residues in theSL (orange inboth structures), helices5and6,CC loop, and
surrounding regions are indicated by arrowsbetween equivalent residues in the sequences. The active-site cysteines are both depicted in green stick representations
(BME adduct in USP4). B, different view of A to highlight conformational differences between the two structures. The color code is as in A.
USP15 catalytic domain structure
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on additional regions for its catalytic turnover, which is largely
consistent with data collected previously on USP15-CD and
FL-USP15 (24) that showedonly aminor effect upon removal of
the N-terminal domains. USP15’s sigmoidal kinetic behavior is
consistent with the occurrence of conformational changes (45).
The USP4 catalytic domain also displays sigmoidal kinetic
behavior (24).
The only other USP shown to have a misaligned catalytic
triad in a structure to date that requires significant conforma-
tional rearrangements for activation is the catalytic domain of
USP7 (USP7-CD) (30, 38). However, in contrast to USP15, the
USP7-CD only displays limited activity, and the C-terminal
UBLs and C terminus are required for full catalytic compe-
tency, whereby they interact with the SL to promote conversion
of the catalytic loop to an -helical conformation and catalytic
triad alignment (46–48). The activity of USP15, on the other
hand, is onlyminimally influenced by the presence of additional
domains, as observed by us and others (24), but also has a mis-
aligned catalytic triad, from which we infer a different mecha-
nism of regulation. It is possible that, like USP15 and USP7,
other USPs may also have flexible CC loops that can adopt
catalytically competent and incompetent conformations, as
few free enzyme structures of USPs have been determined to
date, and crystal structures may preferentially select one con-
formation. Moreover, binding partners may also influence the
competency state of the catalytic triad.
Furthermore, we show that mitoxantrone weakly inhibits
USP15 and determined amitoxantrone–USP15 complex struc-
ture. Only recently, the first USP–inhibitor complex structures
have been published, namely for USP7 (49–51) and USP2 (52).
These either occupy the ubiquitin GG tail–binding cleft (non-
covalently or covalently linked to the active-site cysteine) (51),
compete with distal ubiquitin binding (50), or act noncompeti-
tively (52). Here, we describe a novel binding mode for a USP
whereby a small molecule interacts with the S1 region and
therefore may interfere with proximal substrate moiety inter-
actions (Fig. 6F). Mitoxantrone is a promiscuous binder with
several targets described to date, including DNA-bound topo-
isomerase II  (53), focal adhesion kinase (FAK) (54), human
serine/threonine kinase Pim1 (26), andUSP11 (25). In available
crystal structures of PIM1 (PDB codes 4RC2, 4RBL, and 4I41
(26)) and type II topoisomerase (PDB code 4G0V (55)), mitox-
antrone binding modes also predominantly engage the anthra-
cenedione ring structure mediating interactions with hydro-
phobic residues.
Together, our data shed new light onto the conformational
diversity of ubiquitin-free USP structures, differences between
close paralogs, regulation through incompetent conformational
states, andmodes of small-molecule interactions, which enhances
ourmolecular understanding of theirmodes of action andwill aid
structure-basedmolecular probe and drug design efforts.
Experimental procedures
Cloning, mutagenesis, expression, and protein purifications
Based on bioinformatical analysis, a human USP15 catalytic
core domain construct, USP15-D1D2 (residues 255–919 440-
756) was designed and cloned into pET21d via NcoI and NotI
restriction sites. A small linker (ASTSK) corresponding to the
USP8 sequence was used to link the two catalytic subdomain
halves, D1 and D2, and replace the insertion of 315 residues
that is predicted to contain a high percentage of disorder. FL-
USP15 (UniProtKB identifier Q9Y4E8-2) was cloned via SacI
andHindIII restriction sites into the pCold-I expression vector.
USP15 mutants C269S, C352S, and G860V were created using
primers GTAACTTGGGAAATACGTCTTTCATGAACTC-
AGCTATTCAG/CTGAATAGCTGAGTTCATGAAAGAC-
GTATTTCCCAAGTTAC,AAGCTAACAGTTCTTGACTG-
TCTTGCTGCTGATATCC/GGATATCAGCAGCAAGAC-
AGTCAAGAACTGTTAGCTT, and CTATGGAGGGATGG-
GAGTAGGACACTATACTGCTTTTG/CAAAAGCAGTA-
TAGTGTCCTACTCCCATCCCTCCATAG, respectively,
following the QuikChange mutagenesis protocol. The USP15-
D1D2 bl2usp4 loop swap mutant (G857A/G860V) was created
by swapping USP15(Gly857–Gly860; GMGG) for the corre-
sponding USP4 sequence AMGV. The USP4-D1D2 catalytic
core (residues 294–963484–775) with the insertion removed
and replaced with the USP8 ASTSK sequence analogously to
USP15 was cloned into the pProEx-HTb expression vector
using BamHI and HindIII restriction sites. The USP4 C311S
mutant was created using primers GGAAACCTGGG-
AAACACCAGCTTCATGAACTCCGCT/AGCGGAGTTCA-
TGAAGCTGGTGTTTCCCAGGTTTCC.
All USP constructs were expressed in 2YT broth medium
using the Escherichia coli BL21-CodonPlus strain. Cells were
grown at 37 °C toA600 of0.6 and further grown after induc-
tion by 0.5mM isopropyl 1-thio--D-galactopyranoside over-
night at 25 °C (USP15-D1D1 and USP4-D1D2 constructs)
or 48 h at 10 °C (FL-USP15) after induction. Cells were
harvested, lysed by sonication, and clarified by centrifu-
gation. USP proteins were lysed into 50 mM Tris-Cl, pH 7.5,
300 mM NaCl, 5 mM imidazole, and 1% glycerol (10% for
FL-USP15). Proteins were then loaded onto a HiTrap chelat-
ing column precharged with nickel ions and eluted by an
imidazole gradient. This was followed by size-exclusion
chromatography using a buffer of 20 mM Tris-Cl, pH 7.5, 150
mM NaCl, and 1% glycerol on a Superdex200 16/60 column
(GE Healthcare). Fractions were analyzed by SDS-PAGE,
and relevant fractions were combined and concentrated for
further use.
Enzymatic and inhibition assays
Kinetic parameters for FL-USP15 and USP15-D1D2 were
derived from deubiquitinating assays with concentrations in
the range of 0.1–1.5M ubiquitin-AMC as the fluorogenic sub-
strate and 38 nM FL-USP15 or USP15-D1D2 in 150 mM NaCl,
50 mM Tris-Cl, pH 7.5, 1 mM DTT. Measurements were taken
in 30-l final volumes in triplicate in 384-well black plates
(Nunc) read with an EnVision 2104 multilabel plate reader at
25 °Cusing an excitationwavelength of 355 nmand an emission
wavelength of 426/428 nm. Measurements were taken every
minute for the first 20 min and then every 2 min for the next 30
min and subsequently at increasing intervals of 5, 10, and 20
min. Curves measured in triplicate were fitted using nonlinear
regression analysis in GraphPad prism software (allosteric sig-
moidalmodel using the equation,YVmaxXh/(Khalfh	Xh))
USP15 catalytic domain structure
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to establish Khalf (referred to as Km throughout for consistency
with the literature) and kcat values.
Gel shift linear diubiquitin cleavage assays were carried out
in triplicate in two independent experiments at 25 °C in 50 mM
Tris-Cl, pH 7.5, 300 mM NaCl, 1% glycerol, and 1 mM DTT.
Mitoxantrone was solubilized in the assay buffer, and its con-
centration was determined bymeasuring the absorbance at 682
nmusing an extinction coefficient of 8360M1 cm1. Reactions
were initiated by the addition of linear diubiquitin to FL-
USP15, resulting in final concentrations of 5 M linear diubiq-
uitin and 400 nMUSP15, respectively. The reactionwas stopped
by the addition of SDS-PAGE loading buffer. Linearity tests
were completed to establish the linear range of the reaction. For
the IC50 curve, mitoxantrone was added to FL-USP15 at speci-
fied concentrations in the range of 0.5–800 M and pre-in-
cubated for 30 min before the addition of linear diubiquitin.
Reactions were stopped after 30min and analyzed on 18% SDS-
polyacrylamide gels. After staining, gels were scanned and then
analyzed with the ImageJ software where relative amounts of
diubiquitin and monoubiquitin for each point were deter-
mined. The mean monoubiquitin percentage was calculated
and plotted using GraphPad Prism software using nonlinear
regression analysis.
Isothermal titration calorimetry (ITC)
ITC data were measured on a PEAQ ITC instrument
(Malvern). Monoubiquitin or linear diubiquitin samples (200–
600M)were titrated into the sample cell containing 20–60M
USP15-D1D2, USP15-D1D2 C269S, USP15-D1D2 C352S,
USP15-D1D2 G860V, USP15-D1D2 bl2usp4, USP4-D1D2, or
USP4-D1D2 C311S samples in 150 mM NaCl, 50 mM Tris-Cl,
pH 7.5, and 1% glycerol at a temperature of 25 or 37 °C. The
spacing was typically 180 s, and a stirring speed of 750 rpm was
used. Datawere analyzed using the PEAK ITC analysis software
(Malvern) fitting to a one-site binding model.
Protein crystallization, data collection, and structure
determination
Crystallization of USP15-D1D2 was carried out using a pro-
tein concentration of 4 mg/ml in gel filtration buffer at 20 °C in
the presence and absence of inhibitors. Crystals using 0.1 M
Tris-Cl, pH 8.5, and 20% PEG 2000 as crystallization mother
liquor were obtained in the presence of mitoxantrone (1,4-
dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]an-
thracene-9,10-dione) in gel filtration buffer at a 1:10 molar
ratio and cryoprotected by soaking in a mother liquor supple-
mented with 10% glycerol, 5% ethylene glycol, 1.75% dioxane,
and 1.5 mM pan-USP inhibitor PR-619. Crystals belonged to
monoclinic space group P21with unit cell parameters a 48.51
Å, b 62.62 Å, c 62.04 Å, and 104.97° and contained one
molecule in the asymmetric unit. Data of these crystals were
collected at the ESRF beamline ID30A-1 at a wavelength of
0.966 Å and 100 K. Data were processed using XDS (56) and
AIMLESS (57), and the structure was solved by molecular
replacement using coordinates from the humanUSP4 structure
(PDB code 2Y6E (24)) as a search model with PHASER (58).
The inhibitors were not observed in the electron density in
these crystals, and we refer to this as the free enzyme structure
(USP15-free).
USP15 crystals were also obtained by incubating the protein
with a 1:15 molar excess of mitoxantrone before crystalliza-
tion in the condition 0.1 M Na-Hepes, pH 7.0, 14% MPD at
20 °C. These crystals were flash-cooled after soaking in a cryo-
protectant solution of 35% MPD supplemented with 1 mM
mitoxantrone for data collection. Crystals belonged to space
group P21with unit cell parameters of a 62.07Å, b 94.39Å,
c  63.29 Å, and   90.08° containing two molecules in the
asymmetric unit and diffracted to 2.1 Å resolution. A data set
(USP15–mitoxantrone) was collected at beamline I04 at Dia-
mond Light Source at a wavelength of 0.97951 Å and a temper-
ature of 100 K. Data collection statistics for both data sets are
summarized in Table 1.
Model building, refinement, and validation
Model building and adjustments were conducted us-
ing COOT (59). Structure refinement was carried out in
PHENIX (60), and the quality of the model was assessed by
MOLPROBITY (61). For the USP15 structure from the crystals
with one molecule in the asymmetric unit (USP15-free), the
final model consisted of 325 residues with residues in the
BL1, SL, and BL2 loop regions and the C terminus not mod-
eled due to flexibility. The USP15–mitoxantrone complex
data set consisted of two molecules in the asymmetric unit,
whereby one of the molecules clearly displays density for
mitoxantrone in its vicinity (Fig. 6B). The final USP15–
mitoxantrone complex structure consists of 331 and 309 res-
idues in the two copies, respectively, with residues in the BL1
and SL regions and the C terminus not modeled due to flex-
ibility. Further electron density indicated stacking interac-
tions of additional mitoxantrone molecules against the
USP15-interacting mitoxantrone molecule, but these were
not modeled, as their orientation was unclear. In the final
models, there are no Ramachandran outliers with 98%
of residues (USP15-free) and 96% of residues (USP15–
mitoxantrone) located in favored regions, respectively.
Refinement statistics are summarized in Table 1. Figures were
prepared in PyMOL (Schrödinger, LLC).
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